On January 17, Life Technologies announced a partnership agreement with Daan Gene, China's leading molecular diagnostics technology company, to establish Life-Daan Diagnostics, a joint venture in vitro diagnostic technology in China.
According to the reporter, the Life-Daan joint venture's diagnostic headquarters is located in Guangzhou, and will use Life Technologies' 3500Dx gene analyzer and Cycle Sequencing technology to develop molecular diagnostic reagents for cancer, infectious diseases and genetic diseases. In vitro diagnostic analysis provides strong support. Through the establishment of joint ventures, the two companies will expand the application of capillary electrical pulse technology in clinical diagnostic applications in China.
At present, Life Technologies' main business advantage lies in gene sequencing , but it also faces the challenge of competitor Illumina. Therefore, the development of new technologies is the key to the company's continued development, which will help promote the company's early diagnosis of cancer, infectious diseases and genetic diseases.
Speed ​​up development in China
“I am very pleased to see Life Technologies Greater China's partnership with Daan Gene, which will further strengthen our foundation in clinical diagnostics and is a major leap forward in our business in China.†Life Technologies Chairman and Chief Executive Officer Official Gregory Lucier said: “As a leading biotechnology company, we are at the forefront of the rapidly growing medical sector, and joint ventures and their products will play a key role in disease prevention and treatment options, which the Chinese government encourages. It also meets the objectives of the 'Twelfth Five-Year Plan.'
“The joint venture will provide us with technology-leading and cost-effective medical diagnostic related products to serve Chinese healthcare workers. This comprehensively leverages our expertise in platform development and the Daan gene in the clinical diagnostic market. Develop reagent products and their expertise in commercialization," said Dr. Siddhartha Kadia, President of Life Technologies Greater China.
Zhou Xinyu, CEO of Daan Gene, said: "Twenty years ago, Daan cooperated with ABI, the predecessor of Life Technologies, to introduce PCR technology into the field of molecular diagnostics in China, making China the most potential country for clinical application of PCR technology. Today The cooperation with Life Technologies will bring the latter's leading technology products to China's in-vitro diagnostic market. At the same time, it will also bring Daan's products to the international market. We will join hands to become an internationally influential high-tech product for in vitro diagnostics. Business."
At present, in addition to the good operation of the Guangzhou laboratory, the income of the newly opened Hefei, Chengdu, Kunming and Taizhou clinical inspection centers has also increased rapidly, and gradually entered a virtuous circle. As the company continues to accelerate the layout of the nationwide network of clinical inspection services, its overall profitability is expected to increase further in the next two years. The company is a leader in the development, development and application of molecular biology technologies, especially gene diagnostics and reagent products.
Pushing new technology
Life Technologies has always been at the forefront of gene sequencing and analysis. According to the reporter, Life Technologies' 3500Dx Genetic Analyzer is a capillary-based Sanger sequencing product for analyzing human DNA sequences to detect genetic mutations that may cause disease or susceptibility.
Life Technologies' Sanger sequencing products provide strong technical support for the Human Genome Project and become the "gold standard" for gene sequencing because of its accuracy, reliability and ease of use.
The 3500Dx Genetic Analyzer was approved by the State Food and Drug Administration (SFDA) in October 2011 for clinical diagnosis in China.
The company has been pushing new generations of new technologies that are cheaper. However, the diagnostic sequencing market is small but rapidly growing and is currently monopolized by Illumina. Life Technologies expects to gain a share in the diagnostic sequencing market.
To expand the market, Life Technologies announced that it will launch a new sequencing machine based on the first generation of the sequencer Personal Genome Machine: Ion Proton. Developed by Ion Torrent, a subsidiary of Life Technologies, it completes genome sequencing in one day and costs less than $1,000.
By developing Ion Torrent, Life Technologies finally found a way to compete with Illumina, which has not been done by other companies so far. They plan to apply to the US FDA at the end of the year to include Ion Proton on the list of medical devices.
Currently, Illumina is facing a hostile takeover of Roche, which is likely to become a new company under the Roche Diagnostics, and the uncertainty brought about by the merger clearly gives Life Technologies an opportunity. Therefore, for Life Technologies, the introduction of more new technologies at this time may pose challenges to Roche's diagnosis, which has a huge advantage in the Chinese market and a larger market share.
Beard Straight Comb,Straight Beard Comb,Men Hair Straightening Comb,Electric Straight Hair Beard Comb
Shenzhen Jie Zhong Lian Investment Co., Ltd. , https://www.szmeizonscare.com